Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older

BACKGROUND: To determine the efficacy of an adjuvanted recombinant zoster vaccine in reducing the herpes zoster (HZ) burden of illness, HZ burden of interference with activities of daily living, and HZ impact on quality of life. METHODS: The assessments were integrated in two Phase III trials, ZOE-5...

Descripción completa

Detalles Bibliográficos
Autores principales: Curran, Desmond, Oostvogels, Lidia, Heineman, Thomas, Matthews, Sean, McElhaney, Janet, McNeil, Shelly, Diez-Domingo, Javier, Lal, Himal, Andrews, Charles, Athan, Eugene, Berglund, Johan, Campora, Laura, de Looze, Ferdinandus, Korhonen, Tiina, Leung, Edward, Levin, Myron, Volpi, Antonio, Johnson, Robert W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
The Journal of Gerontology: Translational Section
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625590/
https://www.ncbi.nlm.nih.gov/pubmed/29955836
http://dx.doi.org/10.1093/gerona/gly150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625590/
https://www.ncbi.nlm.nih.gov/pubmed/29955836
http://dx.doi.org/10.1093/gerona/gly150

Ejemplares similares